VTRS · 8-K · 20260806PR000037
Product Launch and Transition
Viatris Inc · 2026-08-06 · Importance 40 · Surprise 42 · In source text
Viatris generated approximately $101 million in new product revenues during the second quarter and approximately $172 million year to date. New product revenues include products launched in 2026 and carryover effects from products launched within the prior 12 months. The company identified new product launches as a contributor to Generics growth and expects Gwyn Lo, a low-dose combined hormonal contraceptive patch, to become commercially available later in 2026. FDA also approved generic ferric carboxymaltose injection in three strengths, a substitutable generic version of Injectafer for iron deficiency anemia, chronic kidney disease and iron deficiency.
Key facts
- The Company expects to deliver approximately $450 million to $550 million in new product revenues in full-year 2026 source
- The Company generated approximately $101 million in new product revenues in Q2 2026 and approximately $172 million for the year-to-date source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | +6.7% | The Company expects to deliver approximately $450 million to $550 million in new product revenues in full-year 2026 |